Influence of plasticizer level on the drug release from sustained release film coated and hot-melt extruded dosage forms.
In the current study, the influence of plasticizer level on drug release was investigated for solid dosage forms prepared by hot-melt extrusion and film coating. The properties of two highly water-soluble compounds, diltiazem hydrochloride (DTZ) and chlorpheniramine maleate (CPM), and a poorly water-soluble drug, indomethacin (IDM), were investigated in the melt extrudates containing either Eudragit RSPO or Eudragit RD 100 and triethyl citrate (TEC) as the plasticizer. In addition, pellets containing DTZ were film coated with Eudragit RS 30D and varying levels of TEC using a fluidized bed coating unit. Differential scanning calorimetry (DSC) demonstrated that both CPM and IDM exhibited a plasticization effect on the acrylic polymers, whereas no plasticizing effect by DTZ on Eudragit RSPO was observed. Thermogravimetric analysis (TGA) was used to investigate the thermal stability of the DTZ, Eudragit RSPO and TEC at 140 degrees C, the maximum temperature used in the hot-melt extrusion process. The chemical stability of DTZ and IDM in the extrudate following hot-melt processing was determined by high pressure liquid chromatography (HPLC). Drug release rates of both DTZ and CPM from hot-melt extrudates increased with an increase in the TEC level in the formulations, while the release rate of DTZ from the Eudragit RS 30D-coated pellets decreased with an increase in TEC in the coating dispersion. This phenomenon was due to the formation of a reservoir polymeric structure as a result of the thermal stress and shear stress involved in the hot-melt extrusion process regardless of the TEC level. In contrast, coalescence of the polymer particles in the film coating process was enhanced with higher levels of TEC, as demonstrated by scanning electron microscopy (SEM). The addition of TEC (0% to 8%) in the IDM hot-melt extrudate formulation had no influence on the drug release rate as the drug release rate was controlled by drug diffusion through the inside of the polymeric materials rather than between the polymer particles.
Zhu
Yucun
Y
Solid Dose Research and Development, Kos Pharmaceuticals, Inc., Hollywood, FL 33020, USA. yuzhu@kospharm.com
Mehta
Ketan A
KA
McGinity
James W
JW
D002152:Calorimetry, Differential Scanning; D002744:Chlorpheniramine / Q000737:chemistry; D002851:Chromatography, High Pressure Liquid; D002951:Citrates / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000737:chemistry; D004110:Diltiazem / Q000737:chemistry; D004355:Drug Stability; D006358:Hot Temperature; D007213:Indomethacin / Q000737:chemistry; D008855:Microscopy, Electron, Scanning; D010316:Particle Size; D004364:Pharmaceutical Preparations / Q000008:administration & dosage*; D010968:Plasticizers / Q000737:chemistry*; D011109:Polymethacrylic Acids / Q000737:chemistry; D012995:Solubility; D013056:Spectrophotometry, Ultraviolet; D013678:Technology, Pharmaceutical; D013818:Thermogravimetry; D014867:Water / Q000737:chemistry; D014961:X-Ray Diffraction
D002951:Citrates; D003692:Delayed-Action Preparations; C496966:Eudragit RSPO; D004364:Pharmaceutical Preparations; D010968:Plasticizers; D011109:Polymethacrylic Acids; D014867:Water; D002744:Chlorpheniramine; C023001:ethyl citrate; D004110:Diltiazem; D007213:Indomethacin